caa a22 4500 477072305 CHVBK 20180405111429.0 cr unu---uuuuu 170330e19961101xx s 000 0 eng 10.1007/BF00052507 doi (NATIONALLICENCE)springer-10.1007/BF00052507 Riegger G. Medizinische Klinik und Poliklinik für Innere Medizin II, Universität Regensburg, Regensburg, Germany aut Role of the renin-angiotensin system as a risk factor for control of morbidity and mortality in coronary artery disease [Elektronische Daten] [G. Riegger] Summary: Coronary heart disease is a multifactorial disease, influenced by environmental and genetic factors. Experimental and clinical data show that the renin-angiotensin system has important indications in coronary artery disease by influencing progressive ventricular dilatation, ventricular function, and outcome. Angiotensin II may have direct toxic effects on myocardial cells, induce hypertrophy in noninfarcted areas, activate the sympathetic nervous system, stimulate fibroblast proliferation, vasoconstrict coronary vessels, increase left ventricular afterload, and impair diastolic relaxation. Associations between a polymorphism of the angioten-sinogen gene and angiotensin-converting enzyme gene and the occurrence of myocardial infarction have been reported. Patients with the DD genotype (ACE gene) have higher plasma ACE and myocardial ACE activity. Preliminary data suggest that the DD genotype is associated with more progressive ventricular dilatation post myocardial infarction and with a greater response after ACE inhibition. The DD genotype is also associated with a higher incidence of left ventricular hypertrophy, which may have implications for the induction of hypertrophy in noninfarcted areas. Whatever the mechanisms, chronic ACE inhibition, started early after myocardial infarction, improves survival and reduces mortality and morbidity for major cardiovascular events. Kluwer Academic Publishers, 1996 renin nationallicence angiotensin II nationallicence angiotensin-converting enzyme gene polymorphism nationallicence coronary artery disease nationallicence Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10(1996-11-01), 613-615 0920-3206 10<613 1996 10 10557 https://doi.org/10.1007/BF00052507 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00052507 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Riegger G. Medizinische Klinik und Poliklinik für Innere Medizin II, Universität Regensburg, Regensburg, Germany aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10(1996-11-01), 613-615 0920-3206 10<613 1996 10 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer